Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy

Table 3 Univariate and multivariate analyses of prognostic factors for progression-free survival

Factors	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Age (< 60 vs ≥ 60), years	1.12 (0.77-1.63)	0.562
Sex (male vs female)	1.07 (0.74-1.55)	0.725
Site (stomach vs gastric and esophageal binding)	1.22 (0.85-1.53)	0.305
ECOG (0 vs 1)	1.55 (1.05-2.29)	0.027	1.55 (1.05-2.28)	0.028
Histological (others vs adenocarcinoma)	0.74 (0.49-1.14)	0.173
FAR (low vs high)	2.18 (1.49-3.20)	< 0.001	1.96 (1.33-2.88)	< 0.001
Staging (3 vs 4)	1.55 (1.01-2.38)	0.045	1.49 (0.97-2.29)	0.072
CEA (< 3 vs ≥ 3), ng/mL	1.09 (0.75-1.59)	0.655
Liver metastasis (no vs yes)	1.03 (0.70- 1.51)	0.896
Peritoneal metastasis (no vs yes)	1.12 (0.68-1.83)	0.664
EBV status (infect vs no-infect)	0.85 (0.51- 1.40)	0.517
PD-L1 expression (CPS < 5 vs CPS ≥ 5)	0.48 (0.31-0.75)	0.001	0.46 (0.29-0.73)	< 0.001
MMR status (dMMR vs pMMR)	2.11 (0.77-5.74)	0.144
BMI (< 25 vs ≥ 25), kg/m2	0.47 (0.29-0.76)	0.002	0.51 (0.31-0.82)	0.006

HR: Hazard ratio; FAR: Fibrinogen-to-albumin ratio; ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic-antigen; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.